Opinion|Videos|August 27, 2024
Choosing MDS Therapies: Risk-Based Approaches
Medical experts discuss risk-based approaches to choosing MDS therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide a high level overview of treatment approaches for both lower and higher risk MDS.
- What are the key considerations when selecting between different treatment options for lower risk MDS?
- Please include a discussion of when hypomethylating agents (HMAs) would be used in lower risk disease.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
5
